Neuroanesthesia and Neuroprotection: Where Are We Now?
LZ Xiong
DOI: https://doi.org/10.1097/00029330-200606010-00001
IF: 6.133
2006-01-01
Chinese Medical Journal
Abstract:Neurosurgery especially intracranial surgery is characterized by periods of intense stimulation alternating with periods of minimal pain. Manipulation of the brain itself is not painful to the patient, but the scalp, skull, and meninges are well innervated with pain fibers. Traction on cerebral arteries as well as sensory cranial nerves can be painful. Therefore, the most appropriate choice of drugs or measures for neuroanesthesia should be dependent on a clear understanding of the pharmacological effects of anesthetics as well as the requirements for anesthesia/analgesia in general and the individual neurosurgical case. Besides, the ultimate aim of neuroanesthesia is to provide optimal intracranial operating conditions, maintain an appropriate cerebral hemodynamics to ensure enough cerebral perfusion, protect against ischemic insults and prevent postoperative complications. The anesthetic techniques and the anesthetics used in neuroanesthesia are all geared to these objectives. The changes of neuroanesthesia that have occurred in the past decades show a steady evolution of anesthetic care both in the operating room and the neurocritical care setting. Monitoring of cerebral hemodynamics, cerebral oxygenation and neuronal function during neurosurgical procedures provide information to guide anesthetic and surgical practices based on individual patients. A monitored approach can decrease neuronal injury and neurological deficit associated with cerebral ischemia in surgery and may improve long-term neurologic outcome. Traditionally, electrocardiography, electroencephalography, arterial blood pressure, pulse oximetry, end-tidal capnography, intracranial pressure, urine output and temperature are monitored during neuroanesthesia in operating room. As a result of the technologic evolution, some novel monitoring techniques, including transcranial Doppler sonography (TCD), jugular bulb oximetry (SjO2), near infrared spectroscopy (NIRS), brain tissue oxygenation and cerebral microdialysis have been applied in neuroanesthesia in recent years. TCD has been recommended as a continuous and noninvasive technique to measure relative (semi-quantitative) changes in cerebral blood flow (CBF). Intraoperative hemodynamic management based on TCD monitoring could improve the outcomes of surgical intervention. Another noninvasive monitoring, NIRS, is used to measure regional changes in oxyhemoglobin, deoxyhemo-globin and cytochrome aa3 redox status noninvasively and continuously. However, continuing technical controversies over signal derivation, accuracy, precision, and quantitative ability have limited the clinical application of NIRS. The measurement of SjO2 has proved to be useful in neuroanesthesia. It is widely accepted that monitoring of SjO2 using jugular bulb catheters reflects the global balance between cerebral oxygen delivery and cerebral oxygen consumption. It allows determination of the critical threshold of cerebral perfusion pressure, below which increasing oxygen extraction leads to cerebral hypoperfusion. Brain tissue measurement of PO2, PCO2, and pH reflects the buffering capacity of cerebral tissue and is able to identify the status of brain tissue PO2 during focal cerebral ischemia caused by temporary arterial clipping and resection of arterio-venous malformations.1,2 Intracerebral microdialysis as an intracerebral sampling method for neurosurgery3,4 was found to give important information about tissue damage during neurosurgical procedures and anesthesia. Intracerebral microdialysis can be used intraoperatively but is presumably too complicated and laborious for routine use. The future success of intracerebral microdialysis as a monitoring tool in neurosurgery depends heavily on the choice of, biomarkers their sensitivity, specificity, and predictive value for secondary neurochemical events, and the availability of chemical analysis of the individual markers. It should be realized that a single monitor can not provide accurate information but a multimodal monitoring may provide useful information for clinical practice. How to choose drugs for neuroanesthesia? What are the characteristics of the ideal agents for neuroanesthesia? The ideal drugs should be rapid onset and rapid offset, should maintain hemodynamic stability, decrease cerebral blood volume (CBV) and intracranial pressure, and maintain cerebral autoregulation and CO2 reactivity. It was reported that propofol, even at normocapnia, significantly reduces CBV relative to isoflurane. Hyperventilation reduces CBV in the presence of isoflurane, but it is still higher than that when propofol is used.5 Preventing increases in intracranial pressure (ICP) is an important goal during neuroanesthesia. Like isoflurane, sevoflurane does not increase ICP if used with hyperventilation and at a concentration of 1 MAC or less. The effects of opioids on ICP are still controversial, but the reported increases in ICP appear to be mainly related to the associated drop in blood pressure with compensatory cerebral vasodilatation. Propofol not only does not increase ICP but also has been shown to be effective in reducing elevated ICP.6 It seems that intravenous general anesthetics such as propofol are better choices for neuroanesthesia. But inhalational anesthetics including isoflurane and sevoflurane can also be safely used in neuroanesthesia, especially in the presence of hyperventilation. Protecting the brain from ischemia during neurosurgery is one of the most important concerns for anesthesiologists. Hypothermia has been used as a potent neuroprotective method for a long time. With protective effects against brain ischemia mediated by multiple ways including energy depletion, this method reduces intracellular acidosis, suppresses synthesis of oxygen free radicals, and inhibits excitatory neurotransmitters. Because deep hypothermia has a high risk of infection and arrhythmia, mild hypothermia (32—34°C) has been extensively investigated and the results showed that mild hypothermia facilitates the recovery of animals after focal and global ischemic brain injuries. Unfortunately, however, there is still only limited evidence of brain protection by hypothermia in humans. A recent prospective, randomized, multi-centre clinical trial showed that intraoperative deliberate mild hypothermia dose not improve the neurological outcome after craniotomy for patients with aneurysmal subarachnoid hemorrhage.7 Another promising neuroprotectant is insulin. Also, a randomized, controlled clinical study showed that preventing even moderate hyperglycemia with insulin during intensive care protected the central nervous system.8 The mechanism of insulin-mediated neuroprotection was found through insulin-like growth factors (IGFs) receptors. IGFs and IGF binding proteins ligand inhibitors also showed neuroprotective properties in experimental models of cerebral ischemia.9 Are there any measures that can prevent brain from ischemic injuries in patients undergoing neurosurgical procedures intra-and post-operatively? The concept of preconditioning and ischemic tolerance might enable us to find practical measures to prevent brain damage. In our laboratory, we found that non-ischemic preconditioning measures such as hyperbaric oxygen, isoflurane and electro-acupuncture mimic ischemic preconditioning to induce neuroprotection against ischemia both in the brain and spinal cord.10–15 The underlying mechanism is not fully understood. Our study showed that during hyperbaric oxygen reactive oxygen species (ROS) activate endogenous antioxidant enzymes, which subsequently scavenge the ROS produced during ischemia-reperfusion, and protects the spinal cord from ROS-mediated injury.15 The results of our study might be used clinically. In surgical procedures for cerebral aneurysm, temporary brain artery occlusion is often used to facilitate surgical access and reduce bleeding. Temporary vessel occlusion might produce focal cerebral ischemia. If neurosurgical patients with possible temporary vessel clipping are preconditioned with hyperbaric oxygen, isoflurane and acupuncture, cerebral ischemic damage might be prevented. However, more substantial information about non-ischemic preconditionings must be collected before these can be advocated. How is the neuroprotection induced by anesthetics? Accumulating evidence indicates that anesthetics might be beneficial to injured brain. Barbiturates, propofol, benzodiazepines, etomidate, and most inhalational anesthetics (halothane, isoflurane, sevoflurane, desflurane, xenon) have proven to cause major reduction in cerebral metabolic rate and induce neuroprotection in animals.16–19 But there is an important difference between animal and human studies. Animal studies are commonly conducted with post-ischemic observation of hours to days. Human trials, in contrast, focus on long-term outcome (months or years). Thus, the results and conclusions of most laboratory studies may not be directly applied to clinical patients. Besides, it should be emphasized that anesthetics induce biomolecular responses that might either produce neuroprotection or have sustained effects on brain function, which present with neurocognitive changes during the first few days after anesthesia. Where are we now? Many questions need to be answered. Might anesthetics provide sustained protection of neurosurgical patients against mild cerebral ischemic/hypoxemic insults, which are almost certainly more common in the operating room than the severe insults routinely studied in the laboratory? If so, which anesthetic is the most effective and how much should be administered for how long? Clearly, before answering these questions, the most important step to be taken is to increase the understanding of both specific mechanisms of anesthetic action and the pathobiology of ischemic/traumatic brain injury and how these two phenomena interact. That deserves to be investigated.